As flowers bloom and temperatures climb, spring brings in allergy season for many. When sneezing, itchy eyes or sinus ...

Longitudinal evaluation of SNOT-22 can distinguish patients with chronic rhinosinusitis with nasal polyps who respond quickly ...

Top-line data from Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps expected in ...

It's the first time that Chinese scholars have published a guideline-type document in a top-tier international journal in ...

Notably, patients with nasal polyps experienced improvements in both symptoms and polyp size after ... LYRA), (“Lyra” or the “Company”), a clinical-stage biotechnology company developing ...

The US regulator has asked for additional clinical data ... for chronic rhinosinusitis with nasal polyps (CRSwNP) that have been shown to reduce symptoms. Sanofi/Regeneron's IL-4 and IL-13 ...

Apogee Therapeutics, Inc. had promising results from its APG808 Phase 1b study show potential for every 2-month asthma ...

AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025: Cambridge, UK Wednesday, May 14, 2025, 13:0 ...

Phase III trial data published in The New England Journal of Medicine support Nucala’s role as an add-on biologic therapy to ...

Sanofi and Regeneron's Dupixent (dupilumab) has gained approval from the FDA for chronic spontaneous urticaria (CSU) ...

Following recent approvals in the EU, US and China, the Singapore approval is based on two replicate phase 3 studies that showed Dupixent achieved significant reduction in exacerbations, and also ...